Modified Medical Research Council Dyspnea Scale in GOLD Classification Better Reflects Physical Activities of Daily Living

Munari, Anelise Bauer; Gulart, Aline Almeida; Santos, Karoliny dos; Venâncio, Raysa Silva; Karloh, Manuela; Mayer, Anamaria Fleig

doi:10.4187/respcare.05636

Cited by 95 publications

(47 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On first day and right after the 10th day of treatment, severity of symptoms and treatment efficacy were evaluated according to the data received from the 6-minute walk distance test 15 and validated questionnaires: for the overall -COPD Assessment Test (CAT) 16 and quantitative breathlessness questionnaire -Modified Medical Research Council Dyspnea Scale (mMRC), 17 for the evaluation of the dynamics of respiratory symptoms -COPD patients Clinical COPD Questionnaire score (CCQ), 18 St. George's Respiratory Questionnaire (SGRQ), 19 36-Item Short Form Survey (SF-36) to assess patients' quality of life. 20 At the same time, a sputum microscopic analysis was performed, in which the number of leukocytes was expressed by the numbers: 1 (from 10 to 15 cells), 2 (from 20 to 25 cells), 3 (from 30 to 40 cells), 4 (more than 40 leukocytes), and was estimated according to the results of the quartile distribution of the obtained variation series.…”

Section: Methodsmentioning

confidence: 99%

The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: A randomized single-center study

et al. 2020

View full text Add to dashboard Cite

Introduction: One-third of all the patients with chronic obstructive pulmonary disease (COPD) additionally take mucolytics as per GOLD recommendation due to complaints of productive cough despite their compliance with the basic treatment regimen. Aim: To assess the efficacy and safety of inhaled N-acetylcysteine (NAC) in comparison with oral NAC in patients with COPD. Material and methods: The study included 46 patients with stable COPD and difficult expectoration of sputum who were divided into two groups. The first group (n = 22) took 600 mg/day NAC orally, and the second one (n = 24) inhaled 600 mg/day NAC by a nebulizer for 10 days. In the beginning and after the 10-day treatment the questionnaires (CAT, mMRC, CCQ, SGRQ, SF-36), 6-minute walk distance test and day and night cough symptoms were evaluated, spirometry and sputum analysis were performed. Results and discussion: In the first group, CCQ showed improvement in the status of patients (by 9.7%). The severity of night cough also decreased. Other indices were not changed statistically. In the other group, positive changes in the CAT (by 13.1%) and SF-36 were reported, night cough decreased. Additionally, forced expiratory volume in 1 s (FEV1) values increased (by 10.3%). No changes in FEV1 2 hours after the first oral usage or inhalation of NAC were found. Conclusions: Both oral administration and inhalation of NAC by a nebulizer for 10 days has a similar positive effect on the manifestations of COPD, but the inhalation route of the drug is also accompanied by improved quality of life and lung function test (FEV1) as well.

show abstract

Section: Methodsmentioning

confidence: 99%

The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: A randomized single-center study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The simpli ed cardiac and respiratory evaluation allows to measure the usual parameters with the mMRC dyspnea scale [12] and the Borg scale [13]. The peak cough ow rate (PCFr) is also measured [14][15].…”

Section: Level 1: the Speci C Covid-19 Evaluationmentioning

confidence: 99%

Geriatric rehabilitation and Covid-19 : a Case Report

Brika

Bossu

Fautrelle

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction : Covid-19 infection has particularly affected older adults. Clinical observations in this population highlight major respiratory impairment associated with development or aggravation of frailty state.Case Presentation : Mr P is a 93 years old frail patient, hospitalized after a COVID-19 infection. The assessment process of this patient has been supported by an innovative multi-systemic tool developed in view of the COVID-19 clinical consequences and a systemic evaluation of motor functions by the Frail BESTest. This process allowed presenting a mixed clinical picture associating an important respiratory distress (linked with the acute respiratory distress syndrome) and an evident motor frailty. The care plan was developed accordingly, and four assessment were done in the same manner until the return home of Mr PConclusion : This case report allows seeing holistically a COVID-19 clinical picture, showing the different axis of clinical reasoning to enhance the rehabilitation process. Furthermore, this case report illustrate the importance of rehabilitation in the Covid-19 context.

show abstract

“…They are reliable, comprehensive, reproducible and applicable worldwide. 1,8,9 FEV1 is needed for the initial assessment. Based on the FEV1 patients will be placed into GOLD 1-4 based on the FEV1.…”

Section: Assessment Of Symptomsmentioning

confidence: 99%

An Overview of the Non- Pharmacological and Non-surgical Management of Chronic Obstructive Pulmonary Disease

Akwe

Fair

Fongeh

2020

MRAJ

View full text Add to dashboard Cite

Chronic Obstructive Pulmonary Disease (COPD) is a disease which warrants a great attention due to the mortality and morbidity caused by COPD. Once a patient has been diagnosed with COPD, a clear plan of care has to be established. Pharmacological management is usually the initial treatment in addition to prevention. COPD exacerbations impair the patient's quality of life and decrease their health status. The decision to start treatment in patient with COPD should be based on the number of symptoms and the risk for exacerbations. Exacerbations will eventually occur in most patients with COPD. The prevention of exacerbations is one of the main goals in the management of COPD. Early recognition and prompt treatment of COPD exacerbation, is very beneficial to the overall outcome of the patient. Stable COPD has several treatment options available based on the stages and so patients within the same stage may be on different treatment regimens. The management of COPD is stepwise. The aim of pharmacological management of COPD is to decrease symptoms and complications. For patients with stable COPD, the treatment goals are to reduce the risk of exacerbation, decrease symptoms and improve exercise tolerance aiming at improving general health and quality of life. This article details the pharmacological management of COPD.

show abstract

Modified Medical Research Council Dyspnea Scale in GOLD Classification Better Reflects Physical Activities of Daily Living

Abstract: The mMRC should be adopted as the classification criterion for symptom assessment in the GOLD ABCD system when focusing on PADL.

Cited by 95 publications

References 43 publications

The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: A randomized single-center study

The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: A randomized single-center study

Geriatric rehabilitation and Covid-19 : a Case Report

An Overview of the Non- Pharmacological and Non-surgical Management of Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About